Bill > S06422

This bill modifies prescription labeling requirements for specific medications related to gender dysphoria treatment, allowing healthcare practices to have their name or address on prescription labels instead of individual prescriber or dispenser names. The bill specifically covers medications like gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, and hormone replacement therapy drugs. Additionally, the bill requires that healthcare prescribers inform patients when they choose to use the practice's name on the prescription label rather than their individual name. The changes aim to provide more flexibility in prescription labeling while ensuring patient transparency, particularly for medications associated with gender-affirming care. The modifications apply to both the dispensing and prescribing aspects of these specific medications, and the bill would take effect immediately upon passage.

Education

https://www.nysenate.gov/legislation/bills/2025/S6422